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The BET inhibitor JQ1 selectively impairs tumour response to
hypoxia and downregulates CA9 and angiogenesis in triple
negative breast cancer
LL da Motta1,2,3, I Ledaki1, K Purshouse1, S Haider1, MA De Bastiani2, D Baban4, M Morotti1, G Steers1, S Wigfield1, E Bridges1, J-L Li1,5,
S Knapp6,7, D Ebner8, F Klamt2, AL Harris1 and A McIntyre1,9
The availability of bromodomain and extra-terminal inhibitors (BETi) has enabled translational epigenetic studies in cancer. BET
proteins regulate transcription by selectively recognizing acetylated lysine residues on chromatin. BETi compete with this process
leading to both downregulation and upregulation of gene expression. Hypoxia enables progression of triple negative breast
cancer (TNBC), the most aggressive form of breast cancer, partly by driving metabolic adaptation, angiogenesis and metastasis
through upregulation of hypoxia-regulated genes (for example, carbonic anhydrase 9 (CA9) and vascular endothelial growth factor
A (VEGF-A). Responses to hypoxia can be mediated epigenetically, thus we investigated whether BETi JQ1 could impair the TNBC
response induced by hypoxia and exert anti-tumour effects. JQ1 significantly modulated 44% of hypoxia-induced genes, of which
two-thirds were downregulated including CA9 and VEGF-A. JQ1 prevented HIF binding to the hypoxia response element in CA9
promoter, but did not alter HIF expression or activity, suggesting some HIF targets are BET-dependent. JQ1 reduced TNBC growth
in vitro and in vivo and inhibited xenograft vascularization. These findings identify that BETi dually targets angiogenesis and the
hypoxic response, an effective combination at reducing tumour growth in preclinical studies.
Oncogene (2017) 36, 122–132; doi:10.1038/onc.2016.184; published online 13 June 2016
INTRODUCTION
Epigenetic regulators are promising targets in cancer as transcrip-
tional dysregulation and mutations in chromatin modulators and
transcription factors (TF) are common in many malignancies. The
bromodomain and extra-terminal (BET) proteins are lysine
acetylation readers that mediate gene expression, including
oncogenes.1 BET inhibitors (BETi) demonstrate many anticancer
effects by downregulating gene expression of oncogenic factors.2
Breast cancer is the most common female cancer and triple
negative breast cancer (TNBC) is its most aggressive subtype. Low
oxygen (hypoxia) can drive TNBC progression,3 promoting
adaptation through genes within the major hallmarks of cancer.4
Hypoxia can control gene expression recruiting chromatin
remodelling complex5 and histone deacetylases.6 Thus, we
investigated whether BETi JQ1 could impair the hypoxia response
in TNBC and exert therapeutic effects.
Hypoxia is found in 450% of breast tumours and arises from
high metabolic and proliferative rates and aberrant tumour
vascularization. Clinically, hypoxia is associated with chemo-
radiotherapy resistance, metastasis and poor survival,7 being a
key area for targeted therapeutic development.3,8 Most hypoxic
responses are mediated by the hypoxia-inducible factors 1α and
2α (HIF-1α and HIF-2α), which in the absence of O2 stabilize and
heterodimerise with HIF-1β.7,9 This heterodimer binds to the
hypoxia response element in gene promoters and induces
transcription of genes, which drive molecular adaptation through
many pathways, including pH regulation (CA9), angiogenesis
(VEGF-A), metabolism (LDHA) and metastasis (LOX).7,8 Other
pathways including the unfolded protein response, XBP1 and
ATF4 are also important.8,10 TNBC shows overexpression of HIF
target genes and is the breast cancer subtype most frequently
associated with hypoxia.11,12 Targeting HIF directly is a major
challenge, while targeting HIF downstream targets such as VEGF
has proven more feasible, although targeting just one protein has
had less effect on overall survival than expected.13–15
The BET proteins (BRD2-4 and BRDT) regulate transcription
by ‘reading’ acetylated histones and recruiting TFs and
epigenetic regulators.1,2 JQ1 is a BETi16 that showed effects
on tumour growth and survival,17 cell cycle arrest, and
differentiation.16,18–20 Although many attributed JQ1 effect to
its MYC downregulation,18,21 it is unlikely that this is the sole
mechanism17 and some studies do not corroborate this,22 as MYC
downregulation is not always sufficient to inhibit cell growth23 and
JQ1 effects are observable without MYC alteration.24 BET proteins
can associate with many TFs21,25 and other genes are regulated by
BETi, such as p21, BCL-xl, BCL2, AKT, FOSL1 and RUNX2.20–22,24
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Although the oncogenic driver varies, tumour addiction to BET
activation seems common to many malignancies. These results led
to clinical evaluation and there are 13 BETi clinical trials currently
underway (www.clinicaltrials.gov).
Given the clinical investigation of BETi, we assessed whether
the BETi JQ1 could alter the hypoxia response, exerting an
anti-tumour effect. JQ1 modulated 44% of hypoxia-responsive
genes, of which two-thirds were downregulated including CA9
and VEGF-A. JQ1 reduced TNBC growth in monolayer and spheroid
culture. Furthermore, JQ1 prevented HIF binding to the CA9
promoter. Finally, JQ1 downregulated CA9 and VEGF-A expression
and reduced growth and vascularization (CD31 positivity) in
a TNBC xenograft model. These data show that JQ1 impairs
tumour response to hypoxia.
RESULTS
JQ1 downregulates the hypoxic transcriptome response
We performed gene array analysis after JQ1 treatment in hypoxia
or normoxia in the TNBC cell line MDA-MB-231 (Figure 1) and
the ER+ MCF-7, as the hypoxic transcriptome of this cell line
is well-documented26 (Supplementary Figure S1). JQ1 alone
profoundly affected gene expression (fold change (FC) log2⩾ 1
and Po0.05, n= 3): 2338 genes were differentially expressed
(DEG) in MDA-MB-231 and 2993 in MCF-7; while hypoxia
induced 119 DEG in MDA-MB-231 and 1286 in MCF-7.
Within the DEG in hypoxia, a considerable proportion were
modulated by JQ1 in hypoxia, 44% in MDA-MB-231 and 29% in
MCF-7 (Figure 1a and Supplementary Figure S1A). Interestingly,
JQ1 had a greater impact on hypoxia-sensitive genes than
those that were not hypoxia-sensitive (P= 0.046; median logFC =
1.22 × 1.02) (Supplementary Figure S1C).
To further investigate the effect of JQ1 on tumour response to
hypoxia, we defined which pathways were hypoxia-regulated and
evaluated their expression under JQ1 treatment. Then, we
developed a Hypoxia Network (HyN) (Figure 1b) containing the
Hypoxia Signature27 and a list of genes for each pathway found to
be hypoxia-regulated (obtained from KEGG, Supplementary Table S1).
Hypoxia upregulated most of the HyN clusters in both cell
lines (Figure 1c and Supplementary Figure S1B). Gene Set
Enrichment Analysis showed that hypoxia upregulates angiogen-
esis, glycolysis, oxidative phosphorylation and pentose phosphate
pathway in MDA-MB-231 (Figure 1c and Supplementary Table S2).
The Hypoxia Signature27 set of genes was upregulated in hypoxia
as expected (MDA-MB-231: ES=−0.79, normalized enrichment
score=− 2.68, Po0.001, false discovery rate q-valueo0.001; MCF-7:
ES=−0.83, normalized enrichment score=−2.63, Po0.001, false
discovery rate q-valueo0.001, n=3). JQ1 treatment prevented
hypoxic upregulation of the hypoxia signature, angiogenesis,
oxidative phosphorylation and pentose phosphate pathway gene
data sets, but did not alter glycolysis or MYC expression. In
addition, JQ1 treatment downregulated the cell cycle and TCA sets
of genes in hypoxia (Figure 1c and Supplementary Table S2).
MCF-7 results confirmed most of these findings (Supplementary
Figure S1B and Supplementary Table S3). CA9 was the
most significantly downregulated gene in both cell lines (MDA-
MB-231: logFC =− 1.40, P= 2.3 × 10− 3; MCF-7: logFC =− 4.22,
P= 1.51 × 10− 9, n= 3) (Figure 1a). The prognostic value in TNBC
of the consistently DEG by JQ1 in hypoxia in both tested cell lines
was evaluated (Figure 1d and Supplementary Figure S2) on
analysis of TCGA data sets http://cancergenome.nih.gov/. Two of
them are associated with poor prognosis in TNBC: CA9 (hazard
ratio = 2.02; P= 0.001) and LOX (hazard ratio = 1.62; P= 0.022)
(Figure 1d).
JQ1 reduces TNBC monolayer and spheroid growth
JQ1 dose-dependently reduced cell growth in monolayer
cultures in all the four TNBC cell lines tested, in hypoxia and
normoxia (Figure 2a and Supplementary Figure S3A). The non-
active enantiomer (− )-JQ116 showed no effect on cell growth
(Figure 2a and Supplementary Figure S3A).
MYC amplification was not a predictor of JQ1 sensitivity
(Figure 2b). JQ1 reduced growth and c-Myc expression of
HCC1806 (Po0.01, n = 3), which has MYC amplification28
and the highest MYC expression among the investigated cell
lines. However, JQ1 did not alter c-Myc, yet induced a similar
growth inhibition in MDA-MB-231 (Figure 2b and
Supplementary Figure S3B), which has no MYC amplification
(cBioPortal).28,29 JQ1 induced a similar growth inhibition in two
additional MYC-non-amplified TNBC cell lines: Cal51 and
SUM159 (Supplementary Figure S3A). No differential effect of
JQ1 on cell growth in two-dimensional culture in normoxia or
hypoxia was identified.
JQ1 inhibited growth of tumour spheroids in all the cell lines
(Figures 2c and d and Supplementary Figure S3C). This model is
more physiologically relevant, as it creates the oxygen, nutrient
and pH gradients found in tumours, and improves the translation
of drug candidates.30 SUM159 did not grow as spheroids. JQ1
reduced spheroid growth rate in MDA-MB-231 (Po0.05, n= 3),
HCC1806 (Po0.05, n= 3) and Cal51 (Po0.01, n= 3). Once again,
the non-active enantiomer (− )-JQ1 did not cause any significant
effect (Figures 2c and d and Supplementary Figure S3C).
JQ1 reduces CA9 and Ki67 expression in TNBC spheroids
Immunohistochemistry showed that untreated spheroids express
CA9 in their hypoxic cores, while JQ1-treated spheroids did
not (MDA-MB-231: Po0.001, n= 3; HCC1806: Po0.01, n= 3)
(Figure 3). JQ1-treated spheroids had lower Ki67 staining,
indicating an anti-proliferative effect (MDA-MB-231: Po0.001,
n= 3; HCC1806: Po0.01, n= 3) (Figure 3). This is concordant with
the downregulation of cell cycle genes by JQ1 in the expression
array analyses (Figure 1c, Supplementary Figure S1B and
Supplementary Tables S2 and S3).
JQ1 reduces expression of CA9, VEGF-A and additional hypoxia
upregulated genes
Quantitative PCR (qPCR) confirmed the JQ1-induced downregula-
tion of hypoxia-responsive genes. CA9 expression was consistently
inhibited by JQ1, without alteration of HIF expression (mRNA and
protein) in all cell lines tested (Figure 4 and Supplementary
Figure S4A).
A panel of 16 genes was investigated including CA9, HIF-1α,
HIF-2α, MYC and genes differentially expressed in the array
analysis (Figure 1). All the HIF targets included in this panel are
upregulated in hypoxia (Figure 4a) and many of them are
downregulated by JQ1 treatment (Figure 4b). Within this panel,
five genes were consistently downregulated by JQ1 treatment in
hypoxia in all cell lines investigated, of which CA9 was the most
prominent (MDA-MB-231: logFC =−2.1, Po0.001; HCC1806:
logFC =− 1.5, Po0.01; MCF-7: logFC =− 5.6, Po0.05). The other
four genes consistently downregulated are VEGF-A, CXCR7,
TMEM45A and LOX. (Figure 4b). Other HIF-regulated genes such
as LDHA or BNIP3 were not affected by JQ1 (Figure 4a), indicating
a specific effect on a subset of the hypoxia transcriptome. MYC
mRNA was downregulated in response to JQ1 treatment in
normoxia and hypoxia, but only in MYC-amplified cell lines
HCC1806 and MCF-7 (Figure 2b, Supplementary Figure S3B,
Figure 4a and Supplementary Figure S4).
Additional BETi were tested (I-BET151 and I-BET762) and
confirmed these findings, also downregulating CA9, VEGF, CXCR7,
TMEM45A and LOX in hypoxia (Supplementary Figure S5). In
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contrast, I-BET151 in hypoxia induced VEGF-A in HCC1806 cell line
and PFKFB3 in both cell lines tested. No effect was observed on
HIF-1α expression, but there was a significant upregulation of
HIF-2α at the RNA level.
Immunoblot analysis further confirmed that JQ1 induced a
significant reduction of CA9 protein induction in hypoxia in both
TNBC cell lines (Po0.01, n= 3) (Figure 4b). JQ1 did not
significantly alter HIF-1α and HIF-2α protein expression
(Figure 4b).
JQ1 reduces HIF binding to the CA9 promoter
To investigate how JQ1 prevents hypoxia-responsive gene
expression, we evaluated chromatin immunoprecipitation (ChIP)
Hypoxia Network (HyN)
Figure 1. JQ1 downregulates the expression of several hypoxia-regulated genes, especially CA9. (a) List of DEG under hypoxia in MDA-MB-231
cells obtained from microarray. Columns at the left denote DEG under JQ1 treatment, either in normoxia (red blocks) or hypoxia (blue dots).
CA9 is the most prominently downregulated gene in hypoxia (red arrow). (b) Hypoxia Network (HyN) created including pathways regulated by
hypoxia. Grey dots are linking genes, included to the network remains stable. (c) Most components of HyN are upregulated by hypoxia and
downregulated by JQ1 treatment in MDA-MB-231 cells. (d) Kaplan–Meier curves demonstrating the prognostic value of two genes
consistently inhibited by JQ1 in both cell lines tested (MDA-MB-231 and MCF-7) for triple negative breast cancer patients. OXPHOS, oxidative
phosphorylation; TCA, tricarboxylic acid cycle; PYR, pyruvate metabolism; PPP, pentose phosphate pathway.
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of HIF-1β to the hypoxia response element of the CA9 promoter,
as HIF-1α dimerizes with HIF-1β prior to transcription induction. As
expected, hypoxia increased HIF binding in both the MDA-MB-231
(P= 0.002, n= 3) and HCC1806 (P= 0.02, n= 3) (Figure 5a). JQ1
treatment in hypoxia reduced HIF binding to the CA9 promoter to
normoxic levels in both MDA-MB-231 (Po0.01, n= 3) and
HCC1806 (Po0.05, n= 3) (Figure 5a). This suggests HIF-1 is BET-
dependent for binding/recruitment in some of its downstream
targets, explaining how BET inhibition reduces the expression of
hypoxia-induced genes.
In addition to this, expressions of BRD2–4 are increased in
hypoxia (Supplementary Figure S6A), suggesting a role for BET
proteins in hypoxia. Although JQ1 is a potent inhibitor for all the
BET proteins,16 some of its effects are attributed to a specific
isoform. We performed siRNA knockdown to investigate which
isoform was responsible for these effects (Supplementary
Figure S6B). BRDT was excluded as its expression was below the
limit of detection. The BRDT siRNA did not change CA9, VEGF or
HIF-1α expression. CA9 expression in hypoxia was reduced after
BRD2 (Po0.01, n= 3), BRD3 (Po0.05, n= 3) and BRD4 (Po0.05,
n= 3) knockdown in MDA-MB-231 cells, without affecting HIF-1α
level (Figure 5b). Only BRD4 (Po0.05, n= 3) reduced VEGF-A
expression in hypoxia (Figure 5b). Therefore, some HIF targets
were shown to be BET-dependent (CA9 and VEGF-A), while others,
such as LDHA are BET-independent.
To better comprehend how JQ1 can have these effects, BRD4
binding and acetylation of H3K27 and H4 in hypoxia at the
promoters of VEGF and CA9 in HCC1806 and MDA-MB-231 were
investigated by ChIP qPCR (Figures 5c and d and Supplementary
Figures S6C and D). A significant increase of BRD4 binding was
identified at the CA9 promoter in hypoxia in HCC1806 cells
(Po0.01, n= 3) (Figure 5c) and at the VEGF promoter in hypoxia in
MDA-MB-231 cells (Po0.05, n= 5) (Figure 5d). A significant
increase for acetylation of H3K27 was found in response to
hypoxia at the CA9 (Po0.05, n= 3) and VEGF (Po0.01, n= 3)
promoters of HCC1806 cells (Figure 5c and Supplementary
MDA-MB-231 spheroids growth
Figure 2. JQ1 reduces TNBC monolayer and spheroid growth, regardless of MYC. (a) Cell cultures were grown in 96-well plates for 72 h in each
condition. (+)-JQ1 dose-dependently reduces monolayer (two-dimensional) cell growth of TNBC cell lines MDA-MB-231 and HCC1806 in
normoxia and hypoxia, while (− )-JQ1 does not. (b) JQ1 reduced c-Myc immunocontent only in the MYC-amplified cell line HCC1806, while the
non-mutated cell line MDA-MB-231 showed no difference in c-Myc. (c) Representative spheroid growth curve and pictures of MDA-MB-231
spheroids following JQ1 treatment. (d) (+)-JQ1 reduces spheroid growth in MDA-MB-231 and other TNBC cell lines, while (− )-JQ1 does not.
One-way analysis of variance, n= 3, *Po0.05, **Po0.01, ***Po0.001.
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Figure S6C) and at the VEGF promoter of MDA-MB-231 (Po0.05,
n= 3) (Figure 5d). There was increased H4 acetylation in response
to hypoxia at the VEGF promoter of MDA-MB-231 (Po0.05, n= 5)
(Figure 5d).
We investigated available BRD4 ChIP-Seq data for MCF-7 in
normoxia31 and compared these with those genes that
were downregulated by JQ1 in hypoxia and found that: 61%
had BRD4 binding by ChIP-Seq in normoxia (Supplementary
Tables S5 and S6). We investigated the BRD4 binding to genes
that were downregulated by JQ1 in hypoxia and also
upregulated in response to hypoxia; 39% of these genes
showed direct binding by BRD4 (Supplementary Tables S5
and S6). Finally, we investigated the overlap between BRD4
binding in normoxia in MCF-731 and HIF-1α or HIF-2α binding
in hypoxia26 in MCF-7 published data sets. These data
confirmed BRD4 and HIF-1 or HIF-2 binding in 14% of
the genes that we identified are increased in hypoxia and
downregulated by JQ1.
JQ1 reduces tumour growth, CA9 and VEGF-A expression, and
vascularization in TNBC xenografts
JQ1 (50 mg/kg) reduced HCC1806 xenograft growth (Po0.05,
n= 5) (Figure 6a) and expression of CA9 (Po0.05, n= 3), VEGF-A
(Po0.05, n= 3), CXCR7 (Po0.05, n= 3) and MYC, but did not affect
the levels of HIF-1α or HIF-2α (Figure 6b).
Despite the downregulation effect observed in VEGF-A expres-
sion, angiogenesis is a broad phenomenon involving multiple
molecular players.7,14,15 We thus investigated the expression of
additional angiogenesis-related genes and observed JQ1-treated
xenografts have lower expression of Tie2 (Po0.05, n= 3) and NRP
(Po0.05, n= 3) and higher expression of EFNB2/ephrinB2
(Po0.05, n= 3) (Figure 6b).
Interestingly, LDH-A (Po0.01, n= 3), BNIP3 (Po0.05, n= 3),
PFKFB4 (Po0.01, n= 3) and TMEM45A (Po0.05, n= 3) (Figure 4a,
Supplementary Figure S4 and Figure 6b) were unaltered or even
downregulated by JQ1 (and other BETi) in cell culture and
upregulated in xenografts.
We investigated the role of JQ1 in angiogenesis due to the
consistent downregulation of VEGF-A found in cell lines
(Figure 4a, Supplementary Figure S4) and the xenografts
(Figure 6b) along with the reduction of the angiogenesis
pathway expression (Figure 1c, Supplementary Figure S1B and
Supplementary Tables S2 and S3). We observed that JQ1-treated
xenografts had lower immunostaining of the blood vessel
marker CD31 (Po0.05), thus indicating an anti-angiogenic
effect of JQ1 (Figure 6c).
DISCUSSION
Hypoxia represents a key target for the development of
therapies in cancer.3,32 Hypoxia induces a transcriptomic shift
largely dependent on HIF,33 and there is evidence for HIF
dependence upon epigenetic regulation in response to
hypoxia.5,6 We demonstrate an epigenetic approach to mod-
ulate the tumour response to hypoxia and reduce growth in
TNBC. JQ1 modulated the expression of 44% of hypoxia-
responsive genes in MDA-MB-231 TNBC cell lines, of which
two-thirds were downregulated. More specifically, JQ1 down-
regulated the expression of the major regulators of hypoxic pH
regulation and angiogenesis, CA9 and VEGF-A, in TNBC cell lines
and xenografts. We observed that in hypoxic conditions, there
was an increased histone acetylation at, and BRD4 binding to,
the CA9 and VEGF promoters, suggesting an explanation for JQ1
effectiveness in this context. It is possible that BRD2 and/or
BRD3 may also be important in the regulation of CA9 and VEGF.
Analysis of published data sets26,31 identified that many of the
hypoxic JQ1-regulated genes have BRD4 binding and that 14%
of the genes simultaneously upregulated by hypoxia, down-
regulated by JQ1 and bound by BRD4 are direct targets of either
HIF-1α or HIF-2α; these included VEGFA and CA9. Finally, as JQ1
prevents HIF binding to the CA9 promoter but not all HIF-
regulated transcription, the data suggest that some HIF targets
are BET-dependent.
JQ1 consistently downregulated CA9 in in vitro and in vivo models.
Hypoxic tumours develop in an acidic microenvironment, owing to
increased production of metabolic acids and poor vascularization.34
CA9 is highly induced in hypoxia, where it allows adaptation to this
environment maintaining a more neutral intracellular pH.35,36
Increased CA9 expression is a marker of poor prognosis in breast
cancer and is more common in TNBC than other breast cancer
subtypes.36 CA9 inhibition reduces tumour growth and metastasis.35–37
Figure 3. JQ1 reduces CA9 and Ki67 stain in TNBC spheroids. CA9 expression is visible in untreated (UT) spheroids, but undetectable in JQ1-
treated spheroids. The proliferative marker Ki67 was also reduced in spheroids treated with JQ1. For immunohistochemistry, spheroids were
fixed with formalin 10%, embedded in agarose, processed, embedded in wax and cut with a microtome. Student t-test, n= 3, **Po0.01,
***Po0.001.
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JQ1 also consistently demonstrated an anti-angiogenic effect,
as it reduced the expression of the angiogenic pathway, the key
angiogenic inducer VEGF-A and blood vessel count. JQ1-treated
xenografts showed lower levels of Tie2 and NRP, involved in
vascular stabilization and branching and promotion of arterial
growth.38 Conversely, there was a higher expression of EFNB2/
ephrinB2 (Figure 6b), described as a regulator of arterial/venous
specialization and vessel branching.38 Collectively, this indicates
that JQ1 could impair the early steps of angiogenesis, a major
hallmark of cancer.
Many studies showed an anti-tumoural effect of BETi,19,21,22,24
and recently it was found that JQ1 shows a typical behaviour of
anti-angiogenic agents and, in fact, JQ1 can reduce tumour
vascularization by suppressing VEGF stimulation.39 Angiogenesis is
upregulated by hypoxia and supports tumour progression.7
Anti-angiogenic therapy is a major cancer treatment strategy
used to treat eight solid tumour types. However, this strategy was
found to induce hypoxia in around 50% of patients.7 Hypoxic
adaptation enables resistance to anti-angiogenic therapy and may
in part explain why the promise of anti-angiogenic therapy in
*p<0.05, **p<0.01, ***p<0.001 compared to untreated normoxia
#p<0.05, ##p<0.01, ###p<0.001 compared to untreated hypoxia
Figure 4. JQ1 reduces CA9 expression in TNBC cell lines. (a) Hypoxia upregulates several genes and JQ1 downregulates a group of them,
CA9 being the most prominent across the three cell lines. HIF expression is not altered by JQ1. (b) CA9 is consistently downregulated by
JQ1 in hypoxia, without any effect on HIF. Cells were treated with JQ1 for 24 h prior to RNA or protein extraction, and then gene expression
was assessed by RT–qPCR and protein immunocontent was assessed by western blot. Two-way analysis of variance, n= 3, *Po0.05, **Po0.01,
***Po0.001.
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Figure 6. JQ1 reduces tumour growth, CA9, VEGF-A and additional angiogenesis-related gene expression and blood vessel count in xenograft
model of TNBC. (a) Growth curve and rate in TNBC xenografts treated with JQ1 or untreated (UT). Linear regression followed by Student t-test,
n= 5, *Po0.05. (b) Gene expression in TNBC xenografts treated with JQ1, assessed by qRT–PCR analysis of RNA extracted from tumours.
Student t-test compared with UT, n= 3, *Po0.05, **Po0.01. (c) Representative CD31 immunostaining in TNBC xenografts. Non-parametric
Mann–Whitney test, n= 3 shCTL and n= 5 JQ1-treated. Xenografts were grown using HCC1806 cells in 6–7-week-old female CD1 nude mice.
Figure 5. JQ1 prevented HIF binding to the CA9 promoter and BET protein knockdowns phenocopy JQ1 treatment. (a) ChIP assay for CA9
promoter region with HIF-1β immunoprecipitation in two TNBC cell lines. Two-way analysis of variance, n= 3. (b) Expression of CA9, VEGF-A
and HIF-1α in hypoxia following siRNA knockdown of BET proteins. One-way analysis of variance, n= 3. (c) ChIP assay for CA9 promoter region
with BRD4, H3K27 acetylation or H4 acetylation immunoprecipitation in HCC1806. T-test, n= 3. (d) ChIP assay for VEGF-A promoter region with
BRD4, H3K27 acetylation or H4 acetylation immunoprecipitation in MDA-MB-231. T-test, n= 3 (H3K27 acetylation) n= 5 (BRD4 and H4
acetylation), *Po0.05; **Po0.01.
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breast cancer has not been fulfilled. We have shown that
combined inhibition of VEGF and CA9 act at least additively and
in some examples synergistically to reduce tumour growth.35
Anti-angiogenic therapies can lead to metabolic adaptation.7,35
JQ1 treatment increased the expression of LDHA and PFKFB4 in
xenografts, but not in cell cultures. LDHA was reported to be
downregulated by JQ1 in ovarian cancer,40 may be because of its
regulation by MYC.41 Whereas JQ1 reduced the expression of
oxidative phosphorylation, pentose phosphate pathway, TCA gene
data sets but not glycolysis in TNBC cell line MDA-MB-231, in the
ER+ cell line MCF-7, JQ1 increased TCA. This may be due to
differences in the metabolic requirements of these subtypes of
breast cancer. Thus, we might expect that a co-treatment with an
anti-glycolytic or pro-OXSPHOS drug (such as metformin) could
lead to a synergistic effect and be a promising therapy, especially
in TNBC.
We also highlight the impact of BET inhibition on wider hypoxic
gene expression. The hypoxic regions of tumours are resistant to
other therapies, therefore we propose that utilizing BET inhibitors
to target the hypoxic tumour cells in combination with additional
chemotherapy or radiotherapy may provide better responses.
Combining hypoxia targeting with radiotherapy or chemotherapy
has been shown previously to provide a greater therapeutic
response. For example, targeting hypoxia-regulated genes includ-
ing CA9, one of the JQ1-regulated genes, increases sensitivity to
radiotherapy and chemotherapy.37,42
Stem cell characteristics comprise another important hallmark
of cancer and epigenetic regulation has an important role in this.
BRD4 has been proposed as a marker for self-renewal43 and JQ1
can downregulate genes involved in this process in human cord-
derived mesenchymal stem cells.44 Stem cells are maintained in an
undifferentiated state through expression of the core transcrip-
tional factors Nanog, Oct4 and Sox2. BRD4 is required for Nanog
expression and JQ1 inhibits this inducing rapid differentiation of
murine embryonic stem cells45,46 as well as significantly down-
regulating Oct4 and SOX2.46 BET inhibition or BRD4 depletion
reduces the expression of pluripotent genes and shifts cellular
fate.45,46 Collectively, these data show that BRD4 is critical for the
maintenance of pluripotency and maintaining stem cell fate, while
inhibition of BET proteins enhances differentiation.
Initially, studies described JQ1 effects as MYC-dependent.16,18,47
Although some studies reported MYC expression predicts JQ1
sensitivity, our results indicate other mechanisms are relevant; as
JQ1 reduced tumour cell growth both in MYC-amplified (MCF-7
and HCC1806) and MYC-non-amplified cell lines (MDA-MB-231,
Cal51 and SUM159). Our data provide further evidence for the
context dependence of BETi.
Several studies show that BETi have broader MYC-independent
effects.19,48,49 JQ1 impairs the recruitment of multiple TFs to their
targets by physical disruption, for example, between the BRD4 and
the N-terminal domain of the androgen receptor.19,21 Thus, JQ1
acts by blocking BET protein ability to bind to chromatin, which in
turn prevents TF recruitment, possibly including HIF. This is in
agreement with our observation of reduced HIF binding to the
CA9 promoter region in response to JQ1. Other important
hypoxia-regulated genes demonstrated a similar pattern of
downregulation by JQ1 in this study. These include CXCR7 and
LOX. CXCR7 is a G protein-coupled receptor upregulated in breast
cancer associated with worst outcome that mediates angiogenesis
and metastasis.50 LOX is also upregulated in breast cancer and
confers a poor prognosis, where it enables angiogenesis51 and
disrupts bone homeostasis providing a favourable environment
for metastatic cells from hypoxic ER− breast cancer.52 Taken
together, this led us to the original suggestion that HIF targets can
be divided into BET-dependent and BET-independent.
The SWI/SNF chromatin remodelling complex was the first
epigenetic factor demonstrated to regulate the response to
hypoxia.5,53 This complex makes DNA accessible to other factors,
especially through its ATPase subunits BRM and BRG1.54 In breast
cancer, BRG1 and BRM are overexpressed in most primary breast
cancers and are needed for in vivo tumour formation and TNBC
cell line proliferation.55 SWI/SNF can either directly regulate the
expression of HIF-1α and HIF-2α or regulate the expression of
hypoxia-responsive genes, including CA9.5 The CA9 promoter
nucleosome is BRG1-depedently remodelled in response to
hypoxia.5 JQ1 does not bind to BRM or BRG1,16 and there is no
current knowledge regarding interactions between BET proteins
and SWI/SNF complex. While JQ1 prevents acetylated histones
from being ‘read’, SWI-SNF can promote deacetylation.54 Both
interact with MYC.16,18,47,54 Finally, just as CA9 was modulated by
both factors, LDHA was not. Future studies should address to what
extent the set of genes affected by these factors overlap. It might
be the case that BET proteins and SWI/SNF complex interact
at some level forming an enhanceosome and only some HIF
targets are epigenetically regulated, rather than being BET- or
SWI/SNF-dependent.
In conclusion, we showed that BETi impairs tumour response to
hypoxia, targeting multiple pathways such as angiogenesis and
pH control. Our findings alter the understanding of tumour
response to hypoxia and identify a new avenue for epigenetic
therapy to target the hypoxic tumour microenvironment. Further-
more, these results have a clear impact on the interpretation of
the results from current clinical trials and future clinical use of
drugs that inhibit the BET proteins in solid tumours.
MATERIALS AND METHODS
Cell culture
Cells were maintained in DMEM+10% FBS at 5% CO2, 37 °C. Hypoxic
incubations: 0.1%O2 in INVIVO2400 workstation (Baker Ruskinn, Sanford,
ME, USA). Cell number was measured by Sulforhodamine B assay56 or
CyQUANT (Molecular Probes, Waltham, MA, USA) following the manufac-
turer’s instructions. Cell lines were purchased from ATCC (Manassas, VA,
USA; MDA-MB-231, HCC1806, MCF-7), Creative Bioarray (Shirley, NY, USA)
(CAL51) and Asterand (Royston, UK) (SUM159); these have stringent quality
control for cell authenticity incorporating short tandem repeat profiling.
Cells were regularly tested for mycoplasma. Stefen Knapp provided JQ1
(University of Oxford, UK) and Daniel Ebner provided I-BET151 and
I-BET762 (University of Oxford, UK).
Spheroid culture
Cells were seeded in round-bottomed plates (Corning, Corning, NY, USA)
with Matrigel (BD Bioscience, Franklin Lakes, NJ, USA)-supplemented
media, aggregated by centrifugation (2000 r.p.m./10 min). Treatment was
daily renewed. Pictures were taken 3 days/week with an inverted
microscope (EVOS xl Core, AMG, Waltham, MA, USA) (n= 3).
Gene expression array and ChIP-Seq data analysis
Illumina whole genome gene expression was performed (n=3 per group).
Biotin-labelled aRNA was hybridized, according to the manufacturer’s
instruction (Illumina Inc., San Diego, CA, USA; #11286340), to high-density
Illumina Human oligonucleotide arrays Human HT-12_V4_0_R1_15002873_B.
Data are available at Array Express (https://www.ebi.ac.uk/arrayexpress/
experiments/E-MTAB-4604/). Fluorescence emissions were detected using
iScanner and data were extracted using BeadStudio v2011.1 Software
(Illumina Inc) and imported to GeneSpring GX 12.1 (Agilent Technologies,
Inc., Santa Clara, CA, USA); Illumina microarray data were pre-processed,
normalized and differential expression analysed using R package LIMMA
(v3.22.4). Significantly DEG were regarded as those with false discovery
rate (Benjamini–Hochberg) corrected P value cutoff of o0.01. Analyses
were performed using R (v3.1.2).
Functional analysis was carried out on DEG to identify statistically
overrepresented ontologies using Database for Annotation, Visualization
and Integrated Discovery (https://david.ncifcrf.gov/). DEG fulfilled the
criteria: FC log2⩾ 1 and Po0.05.
The prognostic value of DEG was generated using The Cancer Genome
Atlas (TCGA) (more information available at http://cancergenome.nih.gov/).
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Genecodis28,29 (http://genecodis.cnb.csic.es/) was used to investigate
pathway alterations. Hypergeometric test was used (false discovery
rate = 0.05). The list of genes comprising these pathways were obtained
from KEGG (http://www.genome.jp/kegg/), GO or the study by Buffa et al.27
(Supplementary Table S3). The Hypoxic Response (HyR) network was
designed in STRING (http://string-db.org/) containing the selected path-
ways (Figure 1b).
Gene Set Enrichment Analysis (v2.1) was used to evaluate pathway
enrichment57 (Supplementary Table S3). ViaComplex (v1.0)58 was used to
generate representative landscape images of these results (Figure 1c and
Supplementary Figure S1B).
Publicly available MCF-7 ChIP-Seq data (GEO dataset GSE55923) was
analysed using MACS2.59 Sequence alignments were performed using
Bowtie v1 (parameters: -v 2 -m 1 -3 1 -S 2) against human genome
assembly hg19. Peaks were called using MACS2 (parameters: --bdg
--nomodel --extsize 283.67 --gsize 2.7e9 --pvalue 1e-3). Peaks were
annotated with gene names (UCSC Hg19 gene annotations version:
September 2014) if they overlapped within 10 000 bp upstream (strand-
specific) or within gene body. For comparisons, each BRD4 replicate was
independently compared with the same MCF-7 Input control. Peaks of
three MCF-7 BRD4 replicates were compared for pairwise correlation using
bigWigCorrelate. Correlation results suggested only modest correlation
(rho 0.4-0.55), therefore replicates were deemed unsuitable for pooling.
Real-time PCR (qPCR)
qPCR was performed (n=3) as described previously.35 Primers sequences
are available in Supplementary Table S4.
Immunoblotting
Immunoblotting was performed as described previously (n=3)35 with
primary antibodies listed in Supplementary Table S7. Bands were
quantified using ImageJ.
Xenograft studies
Mice were housed at BMS, University of Oxford, UK, and procedures were
carried out under a Home Office licence (PPL30/2771). Female Crl:NU-
Foxn1nu mice (Charles River, Oxford, UK) (6–7-week-old) were injected
orthotopically into the mammary fat pad with 2.5 × 106 HCC1806 cells in
1:1 serum-free medium and Matrigel (BD Bioscience) (n=5 animals per
group).
Tumour growth was measured with calipers by experienced technicians
blinded to the experimental hypothesis and after three out of five animals
reached 150 mm3, animals received JQ1 or vehicle (10% DMSO, 10%
hydroxypropyl beta cyclodextrin) intraperitoneally at 50 mg/kg daily.
Animals were randomly grouped at injection and one group was treated
with JQ1 whilst the other was untreated (mean tumour sizes at the
treatment starts were; shCTL, 120 mm3 and JQ1-treated, 137 mm3). When
tumours reached 1.44 cm3, the mice were killed by cervical dislocation.
Immunohistochemistry
Immunohistochemistry was carried out as previously described (n= 3
untreated, n=5 JQ1-treated).35 Slides were submitted to antigen retrieval,
and the primary antibodies listed in Supplementary Table S7. Slides were
incubated with secondary antibody (Dako, Cambridgeshire, UK) and DAB
(Dako) and counterstained with haematoxylin solution (Sigma-Aldrich
Corp., St Louis, MO, USA). Secondary-only control staining was performed
routinely. ImageJ colour deconvolution was used for quantification.35
Gene silencing by RNA interference
Transfections of siRNA duplexes targeting BET proteins (BRD2–4 and BRDT)
or a scramble control (ON-TARGETplus SMARTpool) were performed in
Optimem (Invitrogen, Waltham, MA, USA), using Oligofectamine (Invitro-
gen) (n= 3).
ChIP assay
ChIP assay was performed for antibodies listed in Supplementary Table S7
using the EZ-ChIP Chromatin Immunoprecipitation Kit (#17-371, Millipore,
Billerica, MA, USA) or ChIP-IT Express Enzymatic (Active Motif) according to
the manufacturer’s instructions. DNA isolated from ChIP was quantified by
qPCR using CA9 or VEGF promoter primers (Supplementary Table S4)
(n=3).
Statistical analysis
Statistical analysis and graphs were performed using GraphPad Prism v6.0
(GraphPad, La Jolla, CA, USA). Results are plotted as mean values with
standard deviation. Statistical tests and the number of repeats are
described in the figure legends. Student’s t-test was used for two sample
analyses and normal distributions were assumed, otherwise the non-
parametric Mann–Whitney test was used. Analysis of variance was used for
42 sample analyses. No samples or experimental repeats were excluded
from analyses. For the in vivo experiment to detect a FC of 2 at alpha
(P value) = 0.05, five animals in each group gave a 75% power of detection.
No statistical methods were used for the samples size selection of other
experiments.
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